Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women

References

• Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell G, et al. 2007. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SM. 2008. Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. The Journal of Obstetrics and Gynaecology Research 34:62–66.
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. 2007. Nonalcoholic fatty liver disease and insulin resistance in youth. Diabetes Care 30:1663–1669.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Tendler DA, McMurray RG, Setji TL. 2005. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocrine Practice 11:319–324.
   PubMedGoogle Scholar
• Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, et al. 2007. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Journal of Hepatology 47:412–417.
   PubMed Web of Science ®Google Scholar
• Chang Y, Ryu S, Sung E, Jang Y. 2007. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clinical Chemistry 53:686–692.
   PubMed Web of Science ®Google Scholar
• Daniel WW. 1999. Biostatistics: a foundation for analysis in health sciences. 7th ed. New York: John Wiley and Sons.
   Google Scholar
• Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al. 2010. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51:1593–1602.
   PubMed Web of Science ®Google Scholar
• Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, et al. 2009. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones 8:199–206.
   PubMedGoogle Scholar
• Eigentler T, Lomberg D, Machann J, Stefan N. 2020. Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Annals of Internal Medicine 172: 836–837.
   PubMed Web of Science ®Google Scholar
• Farrell GC, Larter CZ. 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43:S99–S112.
   PubMed Web of Science ®Google Scholar
• Foucher J, Chanteloup E, Vergniol J, Castéra L, Le BB, Adhoute X, et al. 2006. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55:403–408.
   PubMed Web of Science ®Google Scholar
• Gambarin-gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. 2007. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clinical Gastroenterology and Hepatology 5:496–501.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. 2008. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57:1441–1447.
   PubMed Web of Science ®Google Scholar
• Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, et al. 2016. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150:626–637.e7.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. 2001. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850.
   PubMed Web of Science ®Google Scholar
• Markou A, Androulakis II, Mourmouris C, Tsikkini A, Samara C, Sougioultzis S, et al. 2010. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertility and Sterility 93:1220–1226.
   PubMed Web of Science ®Google Scholar
• NCEP Executive Summary. 2001. National Institutes of Health: third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary (NIH publ. no. 01-3670). Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute.
   Google Scholar
• Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. 2014. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis. Hepatitis Monthly 14:e23235.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Spinas G, Rini GB, Carmina E. 2009. Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertility and Sterility 91:1563–1567.
   PubMed Web of Science ®Google Scholar
• [Rotterdam] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19–25.
   Web of Science ®Google Scholar
• Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. 2002. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745–750.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. 2011. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54:344–353.
   PubMedGoogle Scholar
• Stefan N, Haring HU, Cusi K. 2019. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The Lancet. Diabetes & Endocrinology 7:313–324.
   PubMed Web of Science ®Google Scholar
• Stefan N, Schick F, Häring HU. 2017. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metabolism 26:292–300.
   PubMed Web of Science ®Google Scholar
• Stefan N. 2020. Causes, consequences, and treatment of metabolically unhealthy fat distribution. The Lancet. Diabetes & Endocrinology 8:616–627.
   PubMed Web of Science ®Google Scholar
• Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. 2004. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. The Journal of Clinical Endocrinology and Metabolism 89:5454–5461.
   PubMed Web of Science ®Google Scholar
• Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, et al. 2010. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Human Reproduction 25:212–220.
   PubMed Web of Science ®Google Scholar
• Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. 2010. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51:454–462.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. 2000. The Asia-Pacific perspective: redefining obesity and its treatment; [cited 2017 Nov 1]. Available from: http://iris.wpro.who.int/handle/10665.1/5379
   Google Scholar
• World Health Organization. 1999. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization; [cited 2011 Jun 3]. Available from: http://www.whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf
   Google Scholar
• Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, et al. 1998. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Modern Pathology 11:560–565.
   PubMed Web of Science ®Google Scholar